Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 3
1990 1
1991 3
1992 1
1993 3
1994 3
1995 1
1996 2
1997 3
1998 5
1999 1
2000 2
2001 2
2002 2
2003 3
2004 4
2005 3
2006 3
2007 5
2008 1
2009 9
2010 9
2011 8
2012 8
2013 12
2014 4
2015 5
2016 9
2017 7
2018 3
2019 4
2020 2
2021 3
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Short Bouts of Physical Activity-Good for Health?
Wengström Y, Fornander T, Lindström LS. Wengström Y, et al. Among authors: fornander t. JAMA Oncol. 2023 Sep 1;9(9):1199-1201. doi: 10.1001/jamaoncol.2023.1810. JAMA Oncol. 2023. PMID: 37498581 No abstract available.
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS. Johansson A, et al. Among authors: fornander t. J Clin Oncol. 2022 Dec 10;40(35):4071-4082. doi: 10.1200/JCO.21.02844. Epub 2022 Jul 21. J Clin Oncol. 2022. PMID: 35862873 Free PMC article. Clinical Trial.
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Nordenskjöld A, Fohlin H, Rosell J, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström P, Rydén L, Wallgren A, Stål O, Nordenskjöld B. Nordenskjöld A, et al. Among authors: fornander t. Breast. 2023 Oct;71:63-68. doi: 10.1016/j.breast.2023.07.010. Epub 2023 Jul 25. Breast. 2023. PMID: 37517154 Free PMC article. Clinical Trial.
Radiation-induced cardiac disease.
Gyenes G, Fornander T, Rutqvist LE. Gyenes G, et al. Among authors: fornander t. Am Heart J. 1996 Jun;131(6):1236-8. doi: 10.1016/s0002-8703(96)90115-5. Am Heart J. 1996. PMID: 8644615 No abstract available.
[Adverse reactions to anti-hormonal therapy affects adherence].
von Wachenfeldt A, Andersson A, Fornander T, Isaksson Friman E, Johnsson A, Uddbom E, Uttermalm AC. von Wachenfeldt A, et al. Among authors: fornander t. Lakartidningen. 2017 Feb 14;114:EED7. Lakartidningen. 2017. PMID: 28221399 Free article. Swedish. No abstract available.
IP6K2 predicts favorable clinical outcome of primary breast cancer.
Sandström J, Balian A, Lockowandt R, Fornander T, Nordenskjöld B, Lindström L, Pérez-Tenorio G, Stål O. Sandström J, et al. Among authors: fornander t. Mol Clin Oncol. 2021 May;14(5):94. doi: 10.3892/mco.2021.2256. Epub 2021 Mar 12. Mol Clin Oncol. 2021. PMID: 33767863 Free PMC article.
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS. Johansson A, et al. Among authors: fornander t. Int J Cancer. 2022 Jun 15;150(12):2072-2082. doi: 10.1002/ijc.33969. Epub 2022 Mar 7. Int J Cancer. 2022. PMID: 35179782 Free PMC article.
Adjuvant docetaxel for node-positive breast cancer.
Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Martin M, et al. Among authors: fornander t. N Engl J Med. 2005 Jun 2;352(22):2302-13. doi: 10.1056/NEJMoa043681. N Engl J Med. 2005. PMID: 15930421 Free article. Clinical Trial.
VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA. Aguilar H, et al. Among authors: fornander t. Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664. Breast Cancer Res. 2014. PMID: 24886537 Free PMC article.
125 results